secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-09-14T12:59:36+00:00
Accession:  0001437749-26-030236
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio submits FDA briefing package for PH-762; plans Phase 2b in cutaneous squamous cell carcinoma
--------------------------------------------------------------------------------

- Submitted meeting request and comprehensive briefing package to FDA for PH-762, supporting next stage of clinical development.
- Phase 1b study formally completed; planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma.
- Clinical supplies for next study expected available in Q1 2027; toxicology study dosing completed.
- Nonclinical development program and integrated clinical pharmacology data included in briefing package.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926030236/0001437749-26-030236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926030236/phio20260911_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-030236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer